Ipamorelin
Ipamorelin Acetate
Ipamorelin is a growth-hormone secretagogue used in performance and longevity settings, but current FDA treatment keeps it out of normal compounding channels.
Current status
Restricted
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Still discussed as a candidate for future review, particularly in 503B conversations.
Primary Use
Growth-hormone-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: 503B and clinic availability contracted after Category 2 treatment..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Ipamorelin status changes
State-specific notes
Ohio
Office-use sourcing is especially limited.